Tesamorelin vs Sermorelin: GHRH Analog N-Terminal Chemistry
Sermorelin and tesamorelin are both growth hormone-releasing hormone analogs that engage the same pituitary receptor, yet they solve the same chemical problem in opposite ways. One truncates the native peptide to its first 29 residues and leaves the front end exposed. The other keeps all 44 residues and caps the amino terminus with a six-carbon acyl chain. This explainer walks through the sequences, the enzyme that cleaves them, and why the N-terminus is the one region of a GHRH analog that cannot be touched.
by Research Assistant·
On a catalog listing, sermorelin and tesamorelin read like near-twins: two synthetic growth hormone-releasing hormone (GHRH) analogs, both supplied for research use only and not for human or animal consumption of any kind. Look at the chemistry and the resemblance collapses. One is a truncation — the first 29 residues of the native hormone, nothing added. The other is the complete 44-residue sequence wearing a six-carbon cap on its front end. If you're comparing GHRH analogs and wondering why their stability data diverge so sharply, the answer sits almost entirely at the amino terminus. Below: the parent molecule, the two design choices, the single enzyme that explains both, and what the structural gap means for anyone handling these compounds as laboratory reagents.
What a GHRH Analog Actually Is
Short answer: a synthetic version of a hypothalamic signaling peptide, built to engage a pituitary receptor rather than to replace a hormone.
That distinction matters structurally. An analog acts one step upstream of growth hormone itself, so the whole hypothalamic-pituitary regulatory architecture — inhibitory somatostatin tone included — still shapes the resulting secretory pattern. Recombinant growth hormone bypasses that architecture entirely. A receptor agonist doesn't. Both also sit apart from growth hormone secretagogues that act at a different receptor entirely, since the ghrelin-receptor compounds reach the same pituitary cell through a separate door.
Short answer: the native sequence with the back end cut off and nothing added to what remains.
The sequence
Sermorelin is a 29-amino-acid polypeptide corresponding to residues 1 through 29 of human GHRH, and the literature describes it as the shortest fully functional fragment of GHRH. Reported molecular formula is C149H246N44O42S, with a molar mass of 3357.93 g/mol. Chemically, it's bare: a free N-terminal tyrosine, no acyl group, no substituted or non-natural residues anywhere in the chain. What you have is a fragment of the real thing.
What "fully functional" means here
It means residues 30 through 44 aren't required for receptor activation. The 1-29 fragment binds GHRHR and mimics the effects of full-length GHRH in promoting growth hormone secretion. Fifteen residues of the native hormone turn out to be dispensable for the signaling event — a genuinely useful piece of structure-activity information, and the reason a shorter synthesis became the standard research tool.
The chemical liability that comes with it
Leaving the front end native carries a cost. An exposed, unmodified N-terminus hands a particular plasma enzyme precisely the substrate it evolved to recognize. Which brings us to the single fact this whole comparison turns on.
Tesamorelin: One Six-Carbon Cap on Tyrosine-1
Short answer: the whole native sequence, plus a short acyl cap on the front of it.
The modification
Tesamorelin comprises all 44 amino acids of human GHRH carrying a trans-3-hexenoyl group — a six-carbon acyl chain with a double bond at position 3 — anchored to the amino-terminal tyrosine residue. Reported molecular formula is C221H366N72O67S, molar mass 5135.86 g/mol. The literature also records C-terminal amidation, so both ends of the molecule are engineered while the internal backbone stays native — which is why reviews characterize it as a minimally modified GHRH(1-44). No residue substitutions. No backbone redesign. Two termini, two modifications.
The design rationale, stated outright
The peptide-engineering literature doesn't leave the intent to inference. Reviewing strategies for improving peptide developability, researchers record that the addition of a hexenoyl moiety attached to the amino terminus resulted in a molecule found to be resistant to DPP-IV cleavage — aimed squarely at native GHRH's rapid enzymatic clearance. The same review lays out the general toolkit: plasma stability can be increased by blocking the N- or C-terminal ends through N-acylation, N-pyroglutamate, C-amidation, or carbohydrate addition. Tesamorelin reaches for two tools on that list.
Capping versus lipidation — two different tricks
Separate the hexenoyl cap from the long fatty-acid chains that show up elsewhere in peptide chemistry, because they aren't doing the same job. The cap occludes a cleavage site: a short, structural blocking group, nothing more. A C16 fatty acid hung off an internal lysine, as in the liraglutide strategy the same review describes, extends residence time by driving albumin binding instead. Both buy time. Different mechanisms. The side-chain acylation strategies used elsewhere in peptide chemistry make that contrast concrete.
One naming caveat, since both compounds carry International Nonproprietary Names that also correspond to approved pharmaceutical products: research-grade material labeled tesamorelin or sermorelin is not equivalent to, interchangeable with, or a substitute for the FDA-approved pharmaceutical product of the same name.
The DPP-4 Problem: Where the Molecule Breaks
Short answer: one enzyme, one bond, and the peptide stops signaling.
The cleavage site
In plasma, native GHRH — both the (1-44) amide and the (1-40) acid forms — is rapidly cleaved at the 2-3 amino-acid bond, releasing the Tyr1-Ala2 dipeptide and producing GHRH(3-44). Researchers pinned the enzyme's identity by blocking the reaction with diprotin A, a competitive dipeptidyl peptidase-IV inhibitor. The (3-44) fragment was the dominant metabolite observed, and it carries no biological activity — because, as the same work puts it, the first two amino acids are essential for receptor engagement. Two residues gone, signal gone.
The same thing happens to the 1-29 fragment
Truncation offers no shelter here. GRF(1-29) amide is degraded mainly by DPP-IV in plasma to the inactivated GRF(3-29) amide. Isolating the enzyme makes the magnitude plain: adding an equimolar amount of diprotin A extended the measured in-vitro plasma half-life of a GRF(1-29) amide analog to 83.3 minutes. For context, reported pharmacokinetics for GRF(1-29) amide analogs after intravenous delivery in research models fall between 4.7 and 7.4 minutes, with the unmodified parent at 6.2 minutes. A single enzyme accounts for an order-of-magnitude swing in survival time.
A second, slower pathway
DPP-4 isn't the only route. The same plasma work found trypsin-like cleavage at the 11-12 position, with cleavage at the 12-13 site appearing only in the shorter 1-32 and 1-29 constructs. Truncation, in other words, changes the degradation profile rather than simply shortening the chain.
Why the N-Terminus Is the One Part You Cannot Trim
Short answer: the end DPP-4 removes is the exact end the receptor needs.
Two-domain binding
Structural work on the GHRH receptor shows that the N-terminus of GHRH inserts deeply into the receptor's transmembrane domain core, contacting all of the extracellular loops, every transmembrane helix except TM4, and the linker joining the extracellular domain to the transmembrane bundle. That's the canonical class B1 arrangement: the peptide's C-terminal half gets captured by the receptor's extracellular domain and acts as an anchor, while the N-terminal residues descend into the helical bundle and trigger the conformational change that opens the intracellular face for G-protein coupling. The pattern is family-wide rather than GHRH-specific — the same class B GPCR architecture seen in GLP-1R and GIPR follows the same two-domain logic.
The engineering consequence
Set the two findings side by side and the asymmetry jumps out. Receptor-activating information concentrates in the N-terminal region — precisely the region DPP-4 excises. Delete fifteen residues from the C-terminal end, as sermorelin does, and full agonist activity survives. Lose two residues from the N-terminal end and it's finished. That asymmetry is the entire GHRH analog design space in six words: cap the front, trim the back.
Side by Side: What the Numbers Show
Short answer: same receptor, same mechanism, very different chemistry at the ends.
Sequence — sermorelin: human GHRH residues 1-29. Tesamorelin: human GHRH residues 1-44.
N-terminus — sermorelin: free, unmodified Tyr1. Tesamorelin: trans-3-hexenoyl cap on Tyr1.
Molecular formula — sermorelin: C149H246N44O42S. Tesamorelin: C221H366N72O67S.
Molar mass — sermorelin: 3357.93 g/mol. Tesamorelin: 5135.86 g/mol. A gap of roughly 1,800 daltons.
DPP-4 handling — sermorelin: substrate, cleaved to the inactive GRF(3-29). Tesamorelin: reported resistant to cleavage.
Reported half-life — GRF(1-29) amide analogs: roughly 4.7-7.4 minutes after intravenous delivery in research models. Tesamorelin: 26 to 38 minutes in human measurement.
Receptor target — both: GHRHR, a class B1 G-protein-coupled receptor.
Reading the half-life gap
The four-to-five-fold difference tracks the chemistry, not receptor affinity. Both molecules engage the same receptor competently. One survives the dominant plasma protease and one doesn't — that's essentially the whole story.
Pulsatility survives either way
In research with healthy volunteers, the stabilized full-length analog — described in that work as an amidated GHRH(1-44) peptide stabilized against dipeptidyl peptidase IV degradation — increased mean overnight growth hormone concentration and average growth hormone pulse area, with no significant change in the number of pulses. That preserved pulse count is the observable signature of receptor-level agonism: the upstream feedback loop is still running.
What the Structural Difference Means in the Lab
Short answer: the structure sets the handling and characterization expectations.
An 1,800-dalton mass difference is unambiguous by mass spectrometry, so telling the two apart by identity testing is straightforward — and peptide mapping confirms which sequence is actually in the vial rather than merely confirming a mass. The acyl cap changes more than enzymatic stability, too: it shifts the molecule's hydrophobicity, which shows up directly in chromatographic retention behavior during purity work. And an exposed native N-terminus is a reactive chemical handle in a way a capped one isn't — a distinction that belongs in any comparison of the two as reagents.
All of this describes molecular behavior observed in research settings. None of it is a statement about outcomes in people.
Frequently Asked Questions
What is the actual structural difference between tesamorelin and sermorelin?
Sermorelin is GHRH(1-29) — the first 29 residues of native human growth hormone-releasing hormone, chemically unmodified, with a free N-terminal tyrosine. Tesamorelin is the complete 44-residue human GHRH sequence carrying a trans-3-hexenoyl group, a six-carbon acyl chain with a double bond at position 3, attached to that same N-terminal tyrosine. One is a truncation of the native peptide; the other is the full-length peptide with a chemical cap.
Why does the N-terminal modification matter so much?
Dipeptidyl peptidase-4 is the dominant plasma degradation route for GHRH and its native-sequence fragments. It clips the bond between residue 2 and residue 3, removing the Tyr1-Ala2 dipeptide and leaving a fragment that no longer activates the receptor. Structural studies explain why that's fatal: the peptide's N-terminal residues insert deep into the receptor's transmembrane core and carry the activating contacts. Capping the terminus blocks enzyme recognition, so the business end survives.
Are sermorelin and tesamorelin the same molecular weight?
No — they differ by roughly 1,800 daltons. Sermorelin is reported as C149H246N44O42S at 3357.93 g/mol; tesamorelin as C221H366N72O67S at 5135.86 g/mol. The gap comes from the fifteen additional residues, 30 through 44, plus the hexenoyl cap. That difference is wide enough to be unmistakable by mass spectrometry.
Does the longer sequence make tesamorelin a different kind of compound?
Both are GHRH receptor agonists acting at the same target, so they belong to the same mechanistic family. The literature calls tesamorelin minimally modified GHRH(1-44): the internal backbone stays native and the engineering is confined to the termini. Sermorelin, meanwhile, is the shortest fully functional fragment, meaning residues 30 through 44 aren't needed for activation. The 1-29 fragment does the job; the capped full length does it for longer.
Is research-grade material the same as the approved pharmaceutical product?
No. Tesamorelin and sermorelin are International Nonproprietary Names that also correspond to approved pharmaceutical products made under pharmaceutical-grade controls, with their own labeling and regulatory oversight. Research-grade material sold for laboratory use is not equivalent to, interchangeable with, or a substitute for those products. Research-grade peptides are supplied for research use only and are not for human or animal consumption of any kind.
The Bottom Line
Sermorelin and tesamorelin are two answers to the same chemical constraint. DPP-4 attacks the amino terminus of GHRH; the receptor needs that same amino terminus. Sermorelin accepts the liability and keeps a short, native-sequence fragment — perfectly serviceable for research protocols where fast clearance is the point. Tesamorelin caps the terminus with a six-carbon acyl chain and retains all 44 residues, trading synthetic simplicity for a roughly four-to-five-fold longer measured half-life. Neither is the better molecule in the abstract. They're optimized for different questions. And the underlying principle — protect the active terminus — recurs across peptide families, which is why the same logic turns up in GLP-1 and GIP receptor chemistry too.
For research use only. Not for human or animal
consumption of any kind. The information in this article is for
educational purposes only and is not intended to diagnose, treat,
cure, or prevent any disease. The statements made have not been
evaluated by the U.S. Food and Drug Administration. These products
are NOT FDA APPROVED. Please consult with a licensed healthcare
professional before making any decisions regarding your health
or research.
Optides LLC is a chemical supplier. Optides LLC is not a
compounding pharmacy or chemical compounding facility as defined
under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC
is not an outsourcing facility as defined under 503B of the Federal
Food, Drug, and Cosmetic Act.
